Cargando…
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
[Image: see text] The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emphasized the urgency to develop effective therapeutics. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the...
Autores principales: | Zhu, Wei, Xu, Miao, Chen, Catherine Z., Guo, Hui, Shen, Min, Hu, Xin, Shinn, Paul, Klumpp-Thomas, Carleen, Michael, Samuel G., Zheng, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507806/ https://www.ncbi.nlm.nih.gov/pubmed/33062953 http://dx.doi.org/10.1021/acsptsci.0c00108 |
Ejemplares similares
-
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020) -
A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
por: Xu, Miao, et al.
Publicado: (2021) -
A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
por: Xu, Miao, et al.
Publicado: (2022) -
Identifying SARS-CoV-2 Entry Inhibitors through
Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped
Particles
por: Chen, Catherine Z., et al.
Publicado: (2020) -
Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases
por: Jade, Dhananjay, et al.
Publicado: (2021)